Cargando…
Cost of managing complications resulting from type 2 diabetes mellitus in Canada
BACKGROUND: Decision makers need to have Canadian-specific cost information in order to develop an accurate picture of diabetes management. The objective of this study is to estimate direct medical costs of managing complications of diabetes. Complication costs were estimated by applying unit costs...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153533/ https://www.ncbi.nlm.nih.gov/pubmed/12659641 http://dx.doi.org/10.1186/1472-6963-3-7 |
_version_ | 1782120721257857024 |
---|---|
author | O'Brien, Judith A Patrick, Amanda R Caro, J Jaime |
author_facet | O'Brien, Judith A Patrick, Amanda R Caro, J Jaime |
author_sort | O'Brien, Judith A |
collection | PubMed |
description | BACKGROUND: Decision makers need to have Canadian-specific cost information in order to develop an accurate picture of diabetes management. The objective of this study is to estimate direct medical costs of managing complications of diabetes. Complication costs were estimated by applying unit costs to typical resource use profiles. For each complication, the event costs refer to those associated with the acute episode and subsequent care in the first year. State costs are the annual costs of continued management. Data were obtained from many Canadian sources, including the Ontario Case Cost Project, physician and laboratory fee schedules, formularies, reports, and literature. All costs are expressed in 2000 Canadian dollars. RESULTS: Major events (e.g., acute myocardial infarction: $18,635 event cost; $1,193 state cost), generate a greater financial burden than early stage complications (e.g., microalbuminuria: $62 event cost; $10 state cost). Yet, complications that are initially relatively low in cost (e.g., microalbuminuria) can progress to more costly advanced stages (e.g., end-stage renal disease, $63,045 state cost). CONCLUSIONS: Macrovascular and microvascular complication costs should be included in any economic analysis of diabetes. This paper provides Canadian-based cost information needed to inform critical decisions about spending limited health care dollars on emerging new therapies and public health initiatives. |
format | Text |
id | pubmed-153533 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1535332003-04-19 Cost of managing complications resulting from type 2 diabetes mellitus in Canada O'Brien, Judith A Patrick, Amanda R Caro, J Jaime BMC Health Serv Res Research Article BACKGROUND: Decision makers need to have Canadian-specific cost information in order to develop an accurate picture of diabetes management. The objective of this study is to estimate direct medical costs of managing complications of diabetes. Complication costs were estimated by applying unit costs to typical resource use profiles. For each complication, the event costs refer to those associated with the acute episode and subsequent care in the first year. State costs are the annual costs of continued management. Data were obtained from many Canadian sources, including the Ontario Case Cost Project, physician and laboratory fee schedules, formularies, reports, and literature. All costs are expressed in 2000 Canadian dollars. RESULTS: Major events (e.g., acute myocardial infarction: $18,635 event cost; $1,193 state cost), generate a greater financial burden than early stage complications (e.g., microalbuminuria: $62 event cost; $10 state cost). Yet, complications that are initially relatively low in cost (e.g., microalbuminuria) can progress to more costly advanced stages (e.g., end-stage renal disease, $63,045 state cost). CONCLUSIONS: Macrovascular and microvascular complication costs should be included in any economic analysis of diabetes. This paper provides Canadian-based cost information needed to inform critical decisions about spending limited health care dollars on emerging new therapies and public health initiatives. BioMed Central 2003-03-21 /pmc/articles/PMC153533/ /pubmed/12659641 http://dx.doi.org/10.1186/1472-6963-3-7 Text en Copyright © 2003 O'Brien et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Research Article O'Brien, Judith A Patrick, Amanda R Caro, J Jaime Cost of managing complications resulting from type 2 diabetes mellitus in Canada |
title | Cost of managing complications resulting from type 2 diabetes mellitus in Canada |
title_full | Cost of managing complications resulting from type 2 diabetes mellitus in Canada |
title_fullStr | Cost of managing complications resulting from type 2 diabetes mellitus in Canada |
title_full_unstemmed | Cost of managing complications resulting from type 2 diabetes mellitus in Canada |
title_short | Cost of managing complications resulting from type 2 diabetes mellitus in Canada |
title_sort | cost of managing complications resulting from type 2 diabetes mellitus in canada |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153533/ https://www.ncbi.nlm.nih.gov/pubmed/12659641 http://dx.doi.org/10.1186/1472-6963-3-7 |
work_keys_str_mv | AT obrienjuditha costofmanagingcomplicationsresultingfromtype2diabetesmellitusincanada AT patrickamandar costofmanagingcomplicationsresultingfromtype2diabetesmellitusincanada AT carojjaime costofmanagingcomplicationsresultingfromtype2diabetesmellitusincanada |